Abstract Number: 0484 • ACR Convergence 2025
Comparable Efficacy of FK-Tocilizumab and Reference Tocilizumab in Rheumatoid Arthritis Patients With and Without Prior Biologic Exposure
Background/Purpose: Biosimilars offer comparable efficacy and safety to their originators, thereby improving patient access to affordable treatments. FK-Tocilizumab (FK-toci) is the first tocilizumab biosimilar approved…Abstract Number: 0180 • ACR Convergence 2025
Digital Transformation in IMID Care: Results from the Implementation of IMIDOC
Background/Purpose: Rheumatoid arthritis (RA) and spondyloarthritis (SpA) are immune-mediated inflammatory diseases (IMIDs) characterized by joint and spinal inflammation, leading to functional impairment. Their management requires…Abstract Number: 2669 • ACR Convergence 2025
RESET-Myositis: Clinical Trial Evaluating Rese-cel (Resecabtagene Autoleucel), A Fully Human, Autologous 4-1BB CD19-CAR T Cell Therapy in Idiopathic Inflammatory Myopathies
Background/Purpose: The goals of treatment for idiopathic inflammatory myopathy (IIM) are to eliminate or reduce inflammation, restore muscle performance, reduce morbidity, and improve a patient’s…Abstract Number: 2456 • ACR Convergence 2025
Predictors of Real-World Remission in Patients with SLE Initiating Belimumab in the USA
Background/Purpose: The Definition Of Remission in SLE (DORIS) criteria were developed to align SLE remission definitions.1,2 Post hoc analyses of clinical trial data demonstrated that…Abstract Number: 2299 • ACR Convergence 2025
Real-world clinical effectiveness of rituximab rescue therapy in patients with progressive interstitial lung disease associated with primary sjögren’s syndrome
Background/Purpose: To evaluate the real-world, long-term effectiveness of rituximab (RTX) as rescue therapy in patients with primary Sjögren’s syndrome-associated interstitial lung disease (pSS-ILD).Methods: Multicentre observational…Abstract Number: 1994 • ACR Convergence 2025
Pharmacokinetics of Ready-to-Use Pegloticase Formulation Compared to Standard Pegloticase Dosing: Data from the AGILE Study
Background/Purpose: Pegloticase is approved for uncontrolled gout as 8-mg infusions admixed in 250 cc of normal saline over 120 minutes or more administered every 2…Abstract Number: 1549 • ACR Convergence 2025
Improvement in Joint Activity in Adults with Systemic Lupus Erythematosus Treated with Anifrolumab: Results from a Real-World Cohort
Background/Purpose: Inflammatory arthritis is a cardinal manifestation of systemic lupus erythematosus (SLE), limiting joint mobility and adversely affecting quality of life.1 Joint activity in SLE…Abstract Number: 1447 • ACR Convergence 2025
Long-term impact of secukinumab on the prevention of psoriatic arthritis in patients with psoriasis: a 5-year pooled analysis of the ERASURE, FIXTURE and SCULPTURE studies
Background/Purpose: Secukinumab is a fully human monoclonal antibody that selectively inhibits interleukin-17A, demonstrating robust and sustained efficacy in moderate to severe psoriasis (PsO) and psoriatic…Abstract Number: 1323 • ACR Convergence 2025
Efficacy of Olokizumab in Treating Comorbid Depression in Patients with Rheumatoid Arthritis: Results of a Single-Center Randomized Controlled Trial
Background/Purpose: Interleukin (IL)-6 plays an important role in the pathogenesis of depression in rheumatoid arthritis (RA) patients. IL-6 inhibitors used to treat patients with RA…Abstract Number: 1090 • ACR Convergence 2025
Quantitative Immunoglobulin Screening Prior to Rituximab Initiation: A Retrospective Cohort Study
Background/Purpose: Rituximab, a monoclonal antibody which binds to the CD20 antigen of B cells, is used in the treatment of many rheumatologic conditions. Due to…Abstract Number: 0588 • ACR Convergence 2025
The effect of biological and targeted synthetic DMARDs on peripheral manifestations in axial spondyloarthritis: a systematic literature review
Background/Purpose: In axial spondyloarthritis (axSpA), peripheral musculoskeletal manifestations (peripheral arthritis, enthesitis, dactylitis) are common and contribute to the burden of disease. Our objective was to…Abstract Number: 0801 • ACR Convergence 2025
Achieving Sustained Lupus Low Disease Activity State and Remission With Ianalumab (VAY736) in Patients with Systemic Lupus Erythematosus: A post hoc Analysis From a Phase II Study
Background/Purpose: Ianalumab, a fully human monoclonal antibody against the B cell–activating factor receptor (BAFF-R), has a dual mechanism of action of B cell depletion through…Abstract Number: 0479 • ACR Convergence 2025
Risk of Arrhythmias Following IL-6 Inhibitor Use; A Pharmacosurvellience Study of FDA Adverse Event Reporting System (FAERS)
Background/Purpose: Interleukin-6 (IL-6) inhibitors, including tocilizumab and sarilumab, are immunomodulatory agents commonly used in the treatment of rheumatoid arthritis and COVID-19. Prior studies have implicated…Abstract Number: 0153 • ACR Convergence 2025
Patient Experience and Implementation of an Electronic Patient-Reported Outcome Measures (ePROM) System for Remote Monitoring in BIOBADASER
Background/Purpose: Patient-Reported Outcome Measures (PROMs) are integral to shared decision-making and quality improvement in rheumatology. They are recommended for monitoring treatment response, assessing quality of…Abstract Number: 2662 • ACR Convergence 2025
Target trial emulation of biologic and targeted synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis-associated interstitial lung disease
Background/Purpose: RA-ILD is associated with high mortality, but the optimal treatment approach is unclear. While immunosuppressants may treat inflammatory components of ILD, there are concerns…
- « Previous Page
- 1
- …
- 10
- 11
- 12
- 13
- 14
- …
- 67
- Next Page »
